

Stock Data

Share Price:	0.67p
Market Cap.:	£18.07m
Shares in issue:	2,696.98m
52 week high/low:	0.77p/0.20p

Company Profile


Sector:	Health Care
Ticker:	APTA
Exchange:	AIM

Activities

Aptamer Group plc ('APTA', 'Aptamer' 'the Group') is a leading provider of custom aptamer selection and development services for a wide range of research, diagnostic and therapeutic applications.

www.aptagroup.com

Share price performance since Admission¹



¹22 December 2021

Source: [LSE](https://www.lse.com)

Past performance is not an indication of future performance.

Turner Pope contact details

Tel:	0203 657 0050
Email:	info@turnerpope.com
Web:	www.turnerpope.com

Andrew Thacker
Corporate Broking & Sales

Barry Gibb
Research Analyst

TPI acts as broker to Aptamer Group plc.

Attention is drawn to the disclaimers and risk warnings at the end of this document.

Retail clients (as defined by the rules of the FCA) must not rely on this document.

Aptamer Group plc

Aptamer has provided an update on its enzyme modulation projects and a development project with a top five pharmaceutical company. These together represent further important advancements in the Group's licensing and development. With multiple non-exclusive licensing opportunities for its first enzyme-modulating Optimiser[®] already in place, Aptamer has now received initial sales forecasts from its first partner for the first commercial enzyme inhibitor in one specific application area. This alone has the potential to cover c.15% of the Group's annual overheads through passive income. With discussions also continuing to rapidly advance with a second partner plus a third having signed a Material Transfer Agreement ('MTA'), a high level of interest in Optimiser[®] binders to provide new solutions in this field is clearly being demonstrated. These present opportunity for relatively quick conversion into additional medium-to-longer term royalty streams, either of which could become substantially larger than the one already indicated. The Group's second enzyme-modulating Optimiser[®] project has now also reached its final development stage, while a top five pharmaceutical customer has placed repeat orders for Optimiser[®] binders to support its expanded internal testing and evaluation of ELISA (enzyme-linked immunosorbent assay) technology. These different milestones further validate the performance of Aptamer's Optimiser[®] platform, underscoring its commercial potential for provision of innovative antibody-alternative solutions, along with broader applications/strategic licensing potential in diagnostics and therapeutics. Retaining IP ownership provides Aptamer with opportunities for future licensing revenues, therein aligning its strategy to build long-term value through repeat business and commercialisation pathways.

First enzyme-modulating Optimiser[®]

Laboratory research and diagnostic assays use a wide variety of enzymes. Many need their activity to be controlled to prevent errors and false results. In this project, Aptamer developed an Optimiser[®] that binds and releases the target enzyme to regulate two different activities, therein ensuring accurate results. Optimisers are capable of providing solutions in a global market for this assay that has been valued at US\$14.6 billion market (source: MarketsandMarkets, 2025. ID: AST 7880).


Aptamer has multiple non-exclusive licensing opportunities for its first enzyme-modulating Optimiser[®]. The status of each is detailed below:

Licence 1: Aptamer has received initial sales forecasts from its first partner for the first commercial enzyme inhibitor in one specific application area. This non-exclusive licensing deal, which is at an advanced stage of negotiation, has the potential to cover approximately 15% of the Group's annual overhead through passive income. This forecast is subject to the partner achieving its projected revenue targets, with commercial sales expected to begin before the end of the 2025.

Licence 2: Aptamer continues to advance licensing discussions with a second partner, a growing global distributor of enzymes, for non-exclusive access to this enzyme-modulating product. Sales forecasts are currently

being finalised for this second licensing agreement. Updates will be provided as discussions progress.

Licence 3: Aptamer has further signed an MTA with a third partner, a leading global distributor of enzymes, to allow this partner to evaluate the technology. This agreement positions the Group for a potential third non-exclusive license in this area, further demonstrating the growing interest in Optimer® binders for enzyme modulation applications and demand for new solutions in this field.



Source: Aptamer, [Technical Investor Update 14 August 2025](#)

Second enzyme-modulating Optimer® project – Now in its final development stage

Following successful completion and customer approval of all earlier phases, Aptamer has advanced its second enzyme inhibitor project to the final development stage. Discussions are already underway regarding a second licensing deal for this reagent, expanding Aptamer's portfolio to include two separate enzyme modulation technologies based on its proprietary Optimer® platform.

Update on ELISA project with top five pharmaceutical customer

A commercial trading update released on 6 November 2024, detailed a project for the development of Optimer® binders to support an ELISA assay. Initially worth up to £205,000, following receipt of positive feedback from a top five global pharmaceutical partner, this work was expanded on 18 August 2025 with a follow-on agreement to advance Optimer® binders into a fully functional ELISA assay.

The customer has evaluated the Optimer® in a parallel application, showing that it significantly outperformed all previously tested antibodies. As a result, the customer has placed repeat orders for the Optimer® to expand internal testing and evaluation of the technology. The developed Optimer® will be used to support a current clinical drug development programme, with licensing agreements for such reagents typically commanding values as much as hundreds of thousands of pounds.

THIS DOCUMENT IS NOT FOR PUBLICATION, DISTRIBUTION OR TRANSMISSION INTO THE UNITED STATES OF AMERICA, JAPAN, CANADA OR AUSTRALIA.

Conflicts

This is a non-independent marketing communication under the rules of the Financial Conduct Authority ("FCA"). The analyst who has prepared this report is aware that Turner Pope Investments (TPI) Limited ("TPI") has a relationship with the company covered in this report. Accordingly, the report has not been prepared in accordance with legal requirements designed to promote the independence of investment research and is not subject to any prohibition on dealing by TPI or its clients ahead of the dissemination of investment research.

TPI manages its conflicts in accordance with its conflict management policy. For example, TPI may provide services (including corporate finance advice) where the flow of information is restricted by a Chinese wall. Accordingly, information may be available to TPI that is not reflected in this document. TPI may have acted upon or used research recommendations before they have been published.

Risk Warnings

Retail clients (as defined by the rules of the FCA) must not rely on this document.

Any opinions expressed in this document are those of TPI's research analyst. Any forecast or valuation given in this document is the theoretical result of a study of a range of possible outcomes and is not a forecast of a likely outcome or share price.

The value of securities, particularly those of smaller companies, can fall as well as rise and may be subject to large and sudden swings. In addition, the level of marketability of smaller company securities may result in significant trading spreads and sometimes may lead to difficulties in opening and/or closing positions. Past performance is not necessarily a guide to future performance and forecasts are not a reliable indicator of future results.

AIM is a market designed primarily for emerging or smaller companies and the rules of this market are less demanding than those of the Official List of the UK Listing Authority; consequently, AIM investments may not be suitable for some investors. Liquidity may be lower and hence some investments may be harder to realise.

Specific disclaimers

TPI acts as broker to Aptamer Group plc ('Aptamer Group') which is listed on the AIM Market of the London Stock Exchange ('AIM'). TPI's private and institutional clients may hold, subscribe for or buy or sell Aptamer Group's securities.

Opinions and estimates in this document are entirely those of TPI as part of its internal research activity. TPI has no authority whatsoever to make any representation or warranty on behalf of Aptamer Group.

General disclaimers

This document, which presents the views of TPI's research analyst, cannot be regarded as "investment research" in accordance with the FCA definition. The contents are based upon sources of information believed to be reliable but no warranty or representation, express or implied, is given as to their accuracy or completeness. Any opinion reflects TPI's judgement at the date of publication and neither TPI nor any of its directors or employees accepts any responsibility in respect of the information or recommendations contained herein which, moreover, are subject to change without notice. Any forecast or valuation given in this document is the theoretical result of a study of a range of possible outcomes and is not a forecast of a likely outcome or share price. TPI does not undertake to provide updates to any opinions or views expressed in this document. TPI accepts no liability whatsoever (in negligence or otherwise) for any loss howsoever arising from any use of this document or its contents or otherwise arising in connection with this document (except in respect of wilful default and to the extent that any such liability cannot be excluded by applicable law).

The information in this document is published solely for information purposes and is not to be construed as a solicitation or an offer to buy or sell any securities or related financial instruments. The material contained in the document is general information intended for recipients who understand the risks associated with equity investment in smaller companies. It does not constitute a personal recommendation as defined by the FCA or take into account the particular investment objectives, financial situation or needs of individual investors nor provide any indication as to whether an investment, a course of action or the associated risks are suitable for the recipient.

This document is approved and issued by TPI for publication only to UK persons who are authorised persons under the Financial Services and Markets Act 2000 and to professional clients, as defined by Directive 2004/39/EC as set out in the rules of the Financial Conduct Authority. This document may not be published, distributed or transmitted to persons in the United States of America, Japan, Canada or Australia. This document may not be copied or reproduced or re-distributed to any other person or organisation, in whole or in part, without TPI's prior written consent.

Copyright © 2025 Turner Pope Investments (TPI) Limited, all rights reserved.